Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Oncotype DX 21-gene assays are recommended for evaluating distant recurrence and guiding decisions on the use of adjuvant therapy in ER+/HER2- breast cancers. However, it cannot be widely applied due to the high cost and time consumption.

Purpose: To identify MRI radiomics signatures within tumor and peritumoral tissues associated with the 21-gene recurrence score (RS) and explore their value in predicting 5-year recurrence in young women with ER+/HER2- breast cancer.

Methods: Two datasets were analyzed; all the enrolled patients were diagnosed with ER+/HER2- breast cancers and underwent preoperative breast MRIs. The radiogenomic development dataset, with RS data obtained from April 2017 to March 2019, was used to identify optimal RS-signatures based on tumoral, peritumoral, and dilation radiomics features as well as clinical-imaging characteristics with the support vector machine method. The prognosis dataset, in which patients aged 18 to 40 years received breast surgery followed by adjuvant chemotherapy from 2012 to 2016, was used to evaluate the prognostic implication of the proposed optimal RS-signatures by measuring 5-year disease-free survival (DFS) with the Cox proportional hazards model.

Results: 159 patients (111 in the training and 48 in the validation groups) and 111 young patients (a mean follow-up time of 49.6 months and a 5-year DFS of 83.8%) were enrolled in these datasets, respectively. Areas under the receiver operating characteristic curve (AUCs) of the three optimal RS-signatures were 0.74 (95% CI: 0.59-0.87), 0.75 (95% CI: 0.61-0.88) and 0.74 (95% CI: 0.59-0.87) respectively. In the prognosis dataset, there were significant differences in survival between the patients in the predicted high-risk and low-risk groups categorized by the above three signatures, and the predicted recurrence risks were independent factors for DFS.

Conclusion: The radiomic signatures within the tumor and peritumoral region exhibited potential to guide decisions on the use of chemotherapy and predict survival.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12403013PMC
http://dx.doi.org/10.1002/cam4.71172DOI Listing

Publication Analysis

Top Keywords

er+/her2- breast
16
optimal rs-signatures
12
mri radiomics
8
radiomics signatures
8
21-gene recurrence
8
recurrence score
8
breast cancers
8
signatures tumor
8
tumor peritumoral
8
prognosis dataset
8

Similar Publications

Sparking malignancy: nicotine as a driver of stemness and metastasis in triple-negative breast cancer.

J Pathol

September 2025

Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.

Triple-negative breast cancer (TNBC) lacks expression of estrogen receptor (ER), progesterone receptor (PR), and HER2, and remains one of the most aggressive and therapeutically challenging breast cancer subtypes, marked by early relapse, metastasis, and limited targeted treatment options. In a recent study published in The Journal of Pathology, Kuo et al provide compelling evidence that nicotine exposure, whether from tobacco smoke or e-cigarette vapor, drives TNBC progression by promoting stem-like and metastatic phenotypes. Integrating clinical datasets, patient tissues, cell lines, and in vivo models, the authors demonstrate that nicotine enhances tumor aggressiveness via coordinated upregulation of CHRNA9 and IGF1R.

View Article and Find Full Text PDF

Hormonal receptor status and lymph nodes involvement in breast cancer: a retrospective study.

Cell Mol Biol (Noisy-le-grand)

September 2025

Assistant Professor of General Surgery, Department of Surgery, College of Medicine, University of Duhok, Kurdistan Region, Iraq.

Hormonal status and lymphatic invasion are two important prognostic factors among cases of breast cancer. This study aims to assess and evaluate the hormonal receptor status and lymph node involvement among female breast cancer patients in Duhok city, Kurdistan region, Iraq. A retrospective cross-sectional study was conducted, involving 156 diagnosed cases of breast cancer who had undergone surgical treatment and laboratory investigations at Azadi Teaching Hospital and Duhok Private Hospital for 30 months.

View Article and Find Full Text PDF

Lactation-associated breast cancer poses diagnostic challenges due to physiological breast changes that may mask malignancies. Triple-negative breast cancer (TNBC) during lactation is rare and aggressive, requiring vigilant evaluation and treatment. This report highlights the diagnostic dilemma of recurrent cystic breast lesions during lactation, which can mimic benign conditions like galactoceles but may conceal aggressive TNBC, leading to potential delays in diagnosis despite initial conservative approaches such as aspiration.

View Article and Find Full Text PDF

Gastric metastasis of breast cancer is rare, and clinical data on its treatment and prognosis are limited at present. Herein, we report a case of gastric metastasis arising from invasive ductal and mucinous carcinoma of the breast and review the literature. A 51-year-old woman was diagnosed with infiltrating and mucinous carcinoma of the right breast accompanied by ipsilateral axillary lymph node and subclavian lymph node metastases.

View Article and Find Full Text PDF

Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer: A Multicenter Retrospective Analysis.

Oncol Res

September 2025

The Breast Center, Cancer Hospital of Shantou University Medical College, Guangdong Provincial Key Laboratory of Breast Cancer Diagnosis and Treatment, Shantou, 515031, China.

Background: Breast cancer remains a leading cause of morbidity and mortality among women worldwide, with significant geographic disparities in its impact. While human epidermal growth factor receptor 2 (HER2)-targeted therapies, such as trastuzumab, have improved outcomes for HER2-positive breast cancer, challenges like therapy resistance persist, highlighting the need for novel treatments. Recent developments in antibody-drug conjugates (ADCs), particularly disitamab vedotin (RC48), show promising efficacy in targeting both HER2-positive and HER2-low expression tumors, warranting further investigation through real-world studies to assess its broader clinical applicability.

View Article and Find Full Text PDF